ProfileGDS5678 / 1450784_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 72% 75% 73% 75% 60% 66% 78% 74% 71% 66% 74% 73% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1601168
GSM967853U87-EV human glioblastoma xenograft - Control 24.6542272
GSM967854U87-EV human glioblastoma xenograft - Control 35.0327975
GSM967855U87-EV human glioblastoma xenograft - Control 44.795473
GSM967856U87-EV human glioblastoma xenograft - Control 54.9245175
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6735660
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0713766
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3347878
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8727674
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4524971
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9580166
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8814474
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7100273
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6021972